Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively
*The following content is generated by AI and is for reference only.
Overview
Selpercatinib (LOXO-292) is a highly selective RET inhibitor used in oncology. Its molecular formula is C24H26F3N7O3, with CAS No. 1854029-65-4.
Application
- Oncology: Treatment of RET fusion-positive non-small cell lung cancer.
- Rare Diseases: Management of RET-mutant medullary thyroid carcinoma.
- Pharmaceutical R&D: Active pharmaceutical ingredient for targeted therapy development.
Precautions
Requires strict clinical monitoring for hepatotoxicity and QT prolongation. Store under controlled conditions at 2°C to 8°C to maintain stability.